Pfizer, Allergan And Schering NMEs Receive Second “Approvable” Letters
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer’s anidulafungin received a second “approvable” letter Nov. 25 for treatment of esophageal candidiasis, FDA said.